Urinary Excretion of microRNAs in Young Fabry Disease Patients with Mild or Absent Nephropathy

Sebastián Jaurretche¹, ²*, Graciela Venera¹, Norberto Antongiovanni³, Fernando Perretta ⁴, Germán R. Perez⁵, ⁶
¹School of Medicine, Instituto Universitario Italiano de Rosario, Rosario, Argentina
²Los Manantiales, Neurosciences Center, Rosario, Argentina.
³Center for Infusion and Study of Lysosomal Diseases, Instituto de Nefrología de Pergamino, Pergamino, Argentina
⁴Intensive Care Unit, Hospital Dr. Enrique Erill, Belen de Escobar, Argentina
⁵School of Biochemical and Pharmaceutical Sciences, Nacional University of Rosario, Rosario, Argentina
⁶Gammalab Grupo Gamma, Rosario, Argentina
Email: *sebastianjaurretche@hotmail.com

Abstract
Fabry disease (FD) clinical manifestations often start in childhood. Among the FD complications, renal failure causes significant morbidity and mortality. Early diagnosis and treatment of FD nephropathy in children may be critical to preserve renal function. In proteinuric progressive nephropathies it has been described that pro-fibrotic miR-21, miR-192, and miR-433 families are activated and that anti-fibrotic miR-29 and miR-200 families are inhibited.

Objective: Analyze urinary excretion of microRNAs related to renal fibrosis in FD patients with mild or absent nephropathy. Patients with confirmed diagnosis of FD under 18 years of age were compared with healthy subjects. Patients were classified into two groups: 1) Patients with urinary excretion profile of microRNAs indicative of renal fibrosis; and 2) Patients with urinary excretion profile of microRNAs not indicative of renal fibrosis. Results: 9 healthy subjects were enrolled in the study (18.66 ± 13.43 years), 4 males and 5 females. All of them presented normal eFGR without pathological albuminuria. FD population: 12 patients (10.33 ± 3.93 years) were studied, 5 males and 7 females. Patients presented 2 different genotypes: L415P (6 patients) and E398X (6 patients). The urinary excretion profile of microRNAs indicative of renal fibrosis was present in 4 patients (2 with L415P genotype and 2 with E398X genotype), all of them with a decreased of miR-29 and/or miR-200. No patient presented increased miR-21, miR-192 and/or miR-433. Decreased α-gal-A activity was the only variable associated with statistical significance (p ≤ 0.01) to urinary excretion profile of microRNA indicative of
renal fibrosis. **Conclusions:** Young FD patients with classical mutations of GLA gene and mild or absent nephropathy could present a profile of urinary excretion of microRNAs indicative of renal fibrosis associated with decreased α-gal-A activity independently of the other variables. Our findings could suggest a regulation of microRNAs not mediated by TGF-β in FD nephropathy.

**Keywords**
Fabry Nephropathy, Biomarkers, Urinary microRNA, Renal Fibrosis, Early Diagnosis

---

### 1. Introduction

Fabry disease (FD) is a multi-organ disease, X-linked α-galactosidase A (α-Gal-A) deficiency which results in the failure in the glycosphingolipids catabolism, particularly, and globotriaosylceramide (Gb3) [1]. The abnormal storage of Gb3 in the lysosomes and other cell compartments starts in fetal life [2], and leads to deteriorated cellular function which in turn causes the symptoms of the disease [1].

FD clinical manifestations often start in childhood and are seen in both males and females [1] [3]. Among the FD complications, renal failure causes significant morbidity and mortality [4]. Whereas in the majority of affected patients, renal involvement is clinically silent in childhood, once becoming evident as overt proteinuria, FD nephropathy leads progressively to renal failure [5].

Thus, measurements of proteinuria and estimated glomerular filtration rate (eGFR) with formulas that use serum creatinine are the cornerstones in the assessment and monitoring of kidney function [5]. However, these tests have low sensitivity in detecting early kidney damage and abnormal values are often late signs of kidney disease, already in the setting of at least partially irreversible structural damage [5]. Proteinuria, which is long considered the first clinical manifestation of FD nephropathy, may start as early as at 10 years of age [6]. It is well known that morphological changes, even irreversible, such as interstitial tubular fibrosis or glomerular sclerosis, precede the onset of pathological albuminuria [7] [8] [9].

Patients may not fully benefit from enzyme replacement therapy (ERT) if starting when proteinuria is clinically manifest or glomerular filtration rate has already declined. Thus, early diagnosis and treatment of FD nephropathy in children may be critical to preserve renal function [5].

Early biomarkers of Fabry disease nephropathy have been studied in affected adult patients with some promising results [10] [11] [12]. Several studies suggest the potential role of microRNAs in kidney function [13]. In others proteinuric progressive nephropathies it has been described that miR-21, miR-192, and miR-433 families are activated (pro-fibrotics), and that miR-29 and miR-200 families are inhibits (anti-fibrotics) [14].
In FD patients the expression of different circulating microRNAs related to cardiovascular complications has been studied [15] [16] [17] [18]. To date, no study has been published on the study of microRNAs related to renal fibrosis in FD young patients with mild or absent nephropathy.

The early indication of ERT in children and adolescents is controversial. It is recommended ERT start in the presence of clinical manifestations in affected patients of both sexes. In asymptomatic patients the time of ERT start is not so clear. While it is recommended to start arbitrarily at 8 to 10 years of age in children with “classic” mutations of the GLA gene; in asymptomatic girls and children with “late onset” mutations, the time of onset remains unclear [19].

The knowledge of early biomarkers of damage could help to better define the appropriate time for ERT start in FD patients at early ages. The purpose of this study is to analyze urinary excretion of microRNAs related to renal fibrosis in FD patients with mild or absent nephropathy.

2. Material and Methods

2.1. Population

Patients with confirmed diagnosis of FD by genetic test of any gender, under 18 years of age, were included. Exclusion criteria were taken for: 1) patients with nephropathy by different etiology to FD, 2) patients who at the time of evaluation had any symptoms or intercurrence, and 3) patients with confirmed diagnosis of FD who refused to participate in the study. The elimination criterion was applied to: patients who meet inclusion criteria and presented some complication related to the collection process of the samples. A population of healthy subjects with similar demographic characteristics was included.

The patients selected were fasting to the laboratory for the extraction of blood samples and first urine in the morning.

All patients had a mutational study by direct sequencing and Multiplex Ligation Probes Amplification (MLPA) [20] [21], and quantification of a-gal-A enzymatic activity by fluorometric method [22]. Decreased or normal enzyme activity was considered at values less than or greater than 4.0 nmol/h/l, respectively. Plasma and urine creatinine were determined by electrochemiluminescence (Roche Diagnostics). Albuminuria was determined by colorimetric method (Roche Diagnostics). The urinary albumin/creatinine ratio was calculated to estimate 24 hour albuminuria [23]. Ratio values 0 to 30 were considered normal, microalbuminuria when 30 to 300, and macroalbuminuria when higher than 300, in at least two samples. eGFR was calculated using Schwartz 09 (modification 2009) equation [24].

2.2. Urine Sample Preparation and microRNAs Extraction

Urine specimen was collected and sent to laboratory for processing immediately. A volume of 10 ml of urine sample was centrifuged at 3000× g for 15 minutes. 9 ml of supernatant was discarded and the remaining milliliter was centrifuged at...
15000× g during 5 minutes at room temperature. The urinary cell pellet was stored at −80˚C until use. The extraction of microRNAs was performed according to the manufacturer’s protocol (NucleoSpinmiRNA Plasma kits, Mach- ney-Nagel, Germany).

2.3. Detection of microRNAs

To detect the urinary expression of miR-21, miR-29 family, miR-192, miR-200 families and miR-433 in the urine sample, reverse transcription (RT) reaction with a stem-loop primer were used. Stem-loop RT primers were designed according to Chen et al. [25]. Sequence data are presented in Table 1. The specificity of the stem-loop RT primers of each microRNAs is determined by an extension of six nucleotides at the 3’ end; this extension is inverse and complementary to the last six nucleotides of the 3’ end of the microRNA.

MicroRNAs were reverse transcribed using Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics). Briefly, 5 µl total eluate was mixed with 1 µM stem-loop RT primer, 0.5 µM dNTPs, 1× RT reaction buffer, 20 U RNase inhibitor,

Table 1. microRNA and primer sequences.

<table>
<thead>
<tr>
<th>microRNA</th>
<th>Type name</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-21</td>
<td>stem-loop primer Loop.21</td>
<td>GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACCGCACTCGATAACAGCTCAACA</td>
</tr>
<tr>
<td></td>
<td>forward primer F.21</td>
<td>CACGCATAATAGCTATACGACTCG</td>
</tr>
<tr>
<td>miR-29a/c</td>
<td>stem-loop primer Loop.29a</td>
<td>GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACCGCACTCGATAACAGCTCAACA</td>
</tr>
<tr>
<td></td>
<td>stem-loop primer Loop.29c</td>
<td>GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACCGCACTCGATAACAGCTCAACA</td>
</tr>
<tr>
<td></td>
<td>forward primer F.29a/c</td>
<td>CACGCATAATACGACTCG</td>
</tr>
<tr>
<td>miR-29b</td>
<td>stem-loop primer Loop.29b</td>
<td>GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACCGCACTCGATAACAGCTCAACA</td>
</tr>
<tr>
<td></td>
<td>forward primer F.29b</td>
<td>CACGCATAATACGACTCG</td>
</tr>
<tr>
<td>miR-192</td>
<td>stem-loop primer Loop.192</td>
<td>GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACCGCACTCGATAACAGCTCAACA</td>
</tr>
<tr>
<td></td>
<td>forward primer F.192</td>
<td>CACGCATAATACGACTCG</td>
</tr>
<tr>
<td>miR-200a</td>
<td>stem-loop primer Loop.200a</td>
<td>GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACCGCACTCGATAACAGCTCAACA</td>
</tr>
<tr>
<td></td>
<td>forward primer F.200a</td>
<td>CACGCATAATACGACTCG</td>
</tr>
<tr>
<td>miR-200b</td>
<td>stem-loop primer Loop.200b</td>
<td>GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACCGCACTCGATAACAGCTCAACA</td>
</tr>
<tr>
<td></td>
<td>forward primer F.200b</td>
<td>CACGCATAATACGACTCG</td>
</tr>
<tr>
<td>miR-200c</td>
<td>stem-loop primer Loop.200c</td>
<td>GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACCGCACTCGATAACAGCTCAACA</td>
</tr>
<tr>
<td></td>
<td>forward primer F.200c</td>
<td>CACGCATAATACGACTCG</td>
</tr>
<tr>
<td>miR-433</td>
<td>stem-loop primer Loop.433</td>
<td>GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACCGCACTCGATAACAGCTCAACA</td>
</tr>
<tr>
<td></td>
<td>forward primer F.433</td>
<td>CACGCATAATACGACTCG</td>
</tr>
<tr>
<td>miR-U6</td>
<td>stem-loop primer Loop.U6</td>
<td>GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACCGCACTCGATAACAGCTCAACA</td>
</tr>
<tr>
<td></td>
<td>forward primer F.U6</td>
<td>GCCCGTGCGAAGGTACG</td>
</tr>
<tr>
<td>Universal</td>
<td>reverse primer R.MIR</td>
<td>CGGTGCACAGGGTCCGAGGT</td>
</tr>
</tbody>
</table>

*Hybridization temperature for qPCR: 60˚C.
10 U Transcriptor RT and made up to 20 µl with H2O. RT was performed at 16˚C for 30 minutes, 42˚C for 30 minutes, 60˚C for 60 minutes and 70˚C for 15 minutes. The resulting cDNA was stored at −80˚C until use.

FastStart Universal SYBR Green Master/ROX (Roche Diagnostics) was used for the qPCR reaction, which was performed according manufacturer’s protocol on a StepOnePlus System (Applied Biosystems). Briefly, 20 µl PCR included 5 µl cDNART product, 1× Master Mix, 0.1 mM microRNA-specific forward primer and 0.1 mM the universal reverse primer. The reactions were incubated at 95˚C for 10 min, followed by 40 cycles of 95˚C for 15 s and 60˚C for 1 min. All reactions were run in triplicate. The sequence data of the primers are presented in Table 1. RT-qPCR was carried out in compliance with the MIQE guidelines [26] [27].

All qPCR reactions were performed in duplicate, followed by melt curve analysis to verify their specificity and identity. Small nucleolar RNA U6 was selected as the endogenous reference control [28]. Relative microRNA expression levels were calculated using the ΔΔCt method as previously described [29].

Peripheral nervous system (PNS) symptoms, gastrointestinal (GI) symptoms, dyshidrosis, angiokeratomas, hearing loss, cornea verticillata and pathological albuminuria were considered typical early symptoms of FD in childhood and adolescence [1] [30] [31]. PNS symptoms were considered the presence of typical crises of neuropathic pain and/or typical acroparesthesias and/or the demonstration of damage of small neurological fibers by Quantitative Sensory Testing (QST) [32] [33]. Dyshidrosis and typical GI symptoms and physical examination were evaluated by questioning [34]. Dermatologist specialist in FD evaluated the presence of angiokeratomas [1]. Hearing loss by alterations of the logoaudiometry test was defined. Presence of cornea verticillata by ophthalmological examination with slit lamp was evaluated [1]. ACR greater than 30 was considered pathological albuminuria [23]. Mayor complications were considered the typical complications of FD adult patients. Cardiac: 1) cardiac fibrosis: presence of typical images in cardiac MRI with gadolinium and/or 2) cardiac ischemia: presence of typical changes in electrocardiogram and/or cardiac perfusion tests and/or 3) cardiac arrhythmia: presence of electrophysiological disorders in electrocardiogram; 4) left ventricular hypertrophy assessed by tissue Doppler echocardiogram and/or cardiac MRI [1] [35]. Renal: decreased eGFR and/or pathological albuminuria. Central nervous system (CNS): cerebral white matter lesions in cerebral MRI angiography and/or clinical stroke were considered by antecedents during the interrogation and physical examination and demonstration of lesion in cerebral MRI angiography [36].

Patients were classified into two groups 1) Patients with urinary excretion profile of microRNAs indicative of renal fibrosis (with increased profibrotic miR and/or decreased miR antifibrotic) and 2) Patients with urinary excretion profile of microRNAs not indicative of renal fibrosis.

2.4. Statistical Analysis

Normal distribution of continuous variables was tested using Shapiro-Wilk Test.
Descriptive statistics are presented as means ± SD or medians and percentiles. To compare demographic, clinical, and laboratory data, the chi-square or Fisher’s exact test, ANOVA, Kruskal-Wallis or the independent t test, were used as appropriate. The Pearson correlation test was used to analyze the association between categorical variables. The Spearman correlation test was used to analyze the association between categorical variables confidence interval was of 95%. Values of p < 0.05 were considered of statistical significance. Urinary excretion of microRNAs was studied as a function of age, gender, α-gal-A activity, genotype, symptoms, pathological albuminuria and eGFR decrease.

The data were processed in an IBM SPSS Statistics 20 database (Statistical Package for Social Sciences version 21).

2.5. Statement on Ethics

The study was carried out in accordance with the Declaration of Helsinki for Human Research and approved by the local Ethics Committee. Written informed consent for inclusion was obtained from each participant.

The patients expressed their willingness to participate in the study and their legal representative or guardian, signed the informed consent; according to local legal regulations.

3. Results

Controls: 9 healthy subjects (18.66 ± 13.43 years) were studied, 4 males and 5 females. All presented normal eGFR without pathological albuminuria.

Screening period: a total of 73 FD patients were evaluated during the study period, 12 patients had inclusion criteria.

FD population: 12 patients (10.33 ± 3.93 years) were studied, 5 males and 7 females. Patients presented two different genotypes: L415P (6 patients) and E398X (6 patients). 5/5 males (100%) and 1/7 females (14.28%) had decreased α-gal-A activity. The mean value of eGFR was 152.33 ± 48.39 ml/min/1.73 m² and ACR was 21.75 ± 37.13 mg/g. 1/5 males (20.0%) and 1/7 (14.28%) females had microalbuminuria. No patient had proteinuria.

There were no significant differences between the age of both populations studied (p = 0.054).

Frequency of clinical manifestations in FD patients is shown in Table 2.

The comparison of the urinary excretion of microRNAs families studied, between control group and FD patients are shown in Figure 1.

The urinary excretion profile of microRNAs indicative of renal fibrosis was present in 4 patients (2 with L415P genotype and 2 with E398X genotype), all for the decrease of miR-29 and/or miR-200. No patient presented increased miR-21, miR-192 and/or miR-433.

Table 3 shows the correlation between the profile of urinary excretion of microRNAs indicative of renal fibrosis and the clinical characteristics of FD patients.
Table 2. Frequency of clinical manifestations in Fabry disease patients.

<table>
<thead>
<tr>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early symptoms</td>
</tr>
<tr>
<td>PNS symptoms</td>
</tr>
<tr>
<td>GI symptoms</td>
</tr>
<tr>
<td>Dyshidrosis</td>
</tr>
<tr>
<td>Angiokeratomas</td>
</tr>
<tr>
<td>Hearing loss</td>
</tr>
<tr>
<td>Cornea verticillata</td>
</tr>
<tr>
<td>Pathological albuminuria</td>
</tr>
</tbody>
</table>

Mayor complications

<table>
<thead>
<tr>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac</td>
</tr>
<tr>
<td>Renal</td>
</tr>
<tr>
<td>CNS</td>
</tr>
</tbody>
</table>

PNS: peripheral nervous system; GI: gastrointestinal; CNS: central nervous system.

Table 3. Correlation between urinary excretion of microRNAs indicative of renal fibrosis and clinical characteristics of Fabry disease patients.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Urinary profile excretion of microRNAs indicative of renal fibrosis. Pearson correlation (p value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>0.031 (0.923)</td>
</tr>
<tr>
<td>Gender</td>
<td>0.478 (0.116)</td>
</tr>
<tr>
<td>α-gal-A activity</td>
<td>0.707 (&lt;0.01)*</td>
</tr>
<tr>
<td>Genotype</td>
<td>0.000 (1.000)</td>
</tr>
<tr>
<td>Symptoms</td>
<td>0.250 (0.433)</td>
</tr>
<tr>
<td>Pathological albuminuria</td>
<td>0.425 (0.169)</td>
</tr>
<tr>
<td>eGFR decrease</td>
<td>0.166 (0.607)</td>
</tr>
</tbody>
</table>

*Correlation is significant at the 0.01 level. eGFR: estimated glomerular filtration rate.

Figure 1. Comparison of urinary microRNAs excretion between control group and Fabry disease patients of pro-fibrotic microRNAs* and anti-fibrotic microRNAs**.
4. Discussion

Most male patients and a significant number of female patients will eventually develop nephropathy without treatment [37] [38]. Nephropathy is one of the major complications of FD and mainly includes reduced glomerular filtration rate and proteinuria [38].

One of the challenges in the field of research of FD nephropathy is the search for noninvasive biomarkers of kidney damage in pre-albuminuric stages, since those currently available and used routinely, lack sensitivity to detect early damage [39].

In our study, we analyzed the urinary excretion of microRNAs in a population of young FD patients and mild or absent nephropathy. Because there are no precedents in the subject, the five families of microRNAs recognized were selected, related to the process of renal fibrosis via TGF-β in other nephropathies, such as diabetic nephropathy [40] [41].

During fibrosis, TGF-β is capable of inducing many fibrogenic genes, such as extracellular matrix proteins, via Smad2, Smad3 or mitogen-activated protein kinases (MAPKs) [14] [40] [41]. TGF-β1 induces miR-21, miR-192 and miR-433, but suppresses the miR-29 and miR-200 families [14] [40]. Recent evidence demonstrates that TGF-β signaling induces the synthesis of fibrosis-related microRNAs either by increasing transcription, or by enhancing post-transcriptional processing of primary microRNA transcript [40]. There are multiple steps of the biogenesis of microRNAs [41]; its detailed description is beyond the scope of this paper. The mature microRNA induces the RISC complex to bind to the 3’ untranslated region of a target messenger RNA (mRNA). This will result in post-transcriptional gene silencing by mRNA degradation or by translation inhibition. Therefore, microRNAs is able to suppress target gene expression by mRNA degradation, translation inhibition or transcriptional inhibition [42].

In this study, a population of patients with two classical mutations of the GLA gene was compared with healthy subjects with similar demographic characteristics. Despite being patients with mutations that originate the severe FD phenotype, because they are young patients, a low prevalence of both early and late complications of FD was observed.

Because FD is a disease of inheritance X-linked, in patients with classical mutations of the GLA gene which cause severe deficits of α-gal-A activity, affected men develop symptoms at an early age and in women that happens at a variable age and severity.

It was observed that the profile of urinary excretion of microRNAs indicative of renal fibrosis present in the patients was produced by decrease of the anti-fibrotic microRNAs (miR-29; miR-200) and not by increase of the pro-fibrotic microRNAs (miR-21; miR-192; miR-433).

In our results, the only variable associated with statistical significance for a profile of urinary excretion of microRNAs indicative of renal fibrosis was low α-gal-A activity. No statistically significant association was found with the rest of the variables studied, even with respect to the sex of the patients.
Although the small size of the population studied may represent a statistical limitation, other studies devoted to similar purposes were carried out with an analogous number of patients. Therefore, considering the low frequency of FD, this work could contribute to the knowledge of the subject.

Young FD patients with classical mutations of the GLA gene and mild or absent nephropathy presented a profile of urinary excretion of microRNAs indicative of renal fibrosis, even in the pre-albumin stage. This profile was produced by decreasing of microRNAs that are down regulated by TGF-β and was significantly correlated with the decrease in α-gal-A activity independently of the other variables studied. Our results would support the theory of initiating ERT treatment in FD patients with decreased levels of α-gal-A in asymptomatic patients with classical GLA mutations.

The decrease of anti-fibrotic microRNAs and the non-increase of pro-fibrotic microRNAs could suggest a regulation of microRNAs not mediated by TGF-β1 in FD nephropathy.

5. Conclusion

Our results show that young FD patients with classical mutations of the GLA gene and mild or absent nephropathy could present a profile of urinary excretion of microRNAs indicative of renal fibrosis associated with statistical significance at decreased α-gal-A activity independently of the other variables studied. A urinary excretion profile of microRNAs could be used as non-invasive biomarkers of early kidney damage due to FD, even in pre-albuminuric stages. The decrease of anti-fibrotic microRNAs and the non-increase of pro-fibrotic microRNAs could suggest a regulation of microRNAs not mediated by TGF-β in FD nephropathy. Longitudinal studies with a larger number of patients would be necessary to confirm this finding.

Data Availability Statement

The data used to support the findings of this study are restricted by the Ethic Committee of the Instituto Universitario Italiano de Rosario in order to protect patients privacity. Data are available from for researchers who meet the criteria for access to confidential data.

Conflicts of Interest

SJ declarations to have received financial contributions from the companies SANOFI-Genzyme, Shire HGT and Biomarin for dissertations on Fabry disease and Mucopolisacaridosis and financial contributions from SANOFI-GENZYME for research projects; the other authors do not have conflicts of interest related to the contents of this work.

Funding Statement

The present work was carried out with the financial support of the SANOFI-
Genzyme company of Argentina, for the purchase of medical supplies used in the laboratory.

References


[12] Aguiar, P., Azevedo, O., Pinto, R., Marino, J., Baker, R., Cardoso, C., Duca Soares,
J.L. and Hughes, D. (2017) New Biomarkers Defining a Novel Early stage of Fabry Nephropathy: A Diagnostic Test Study. *Molecular Genetics and Metabolism, 121*, 162-169. [https://doi.org/10.1016/j.ymgme.2017.05.007](https://doi.org/10.1016/j.ymgme.2017.05.007)


2102-2111. https://doi.org/10.1093/ndt/gfp031


